PL403456A1 - Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3 - Google Patents

Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3

Info

Publication number: PL403456A1
Authority: PL; Poland
Prior art keywords: kinase inhibitors; phenylthiazole derivatives; phenylthiazole; derivatives; kinase
Prior art date: 2002-02-28

Application number

PL403456A

Other languages

English (en)

Other versions

PL219449B1 (pl

Inventor

Ian Bruce

Peter Finan

Catherine Leblanc

Clive Mccarthy

Lewis Whitehead

Nicola Elaine Press

Graham Charles Bloomfield

Judy Hayler

Louise Kirman

Mrinalini Sachin Oza

Lena Shukla

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-28

Filing date

2003-02-27

Publication date

2013-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL403456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-28 Priority claimed from GB0204765A external-priority patent/GB0204765D0/en

2002-12-19 Priority claimed from GB0229626A external-priority patent/GB0229626D0/en

2003-02-27 Application filed by Novartis Ag filed Critical Novartis Ag

2013-05-27 Publication of PL403456A1 publication Critical patent/PL403456A1/pl

2015-04-30 Publication of PL219449B1 publication Critical patent/PL219449B1/pl

Links

ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical class S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 title 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

PL403456A 2002-02-28 2003-02-27 Pochodne 5-fenylotiazolu, zawierające je kompozycje farmaceutyczne oraz lecznicze zastosowania tych związków PL219449B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0204765A GB0204765D0 (en)	2002-02-28	2002-02-28	Organic compounds
GB0229626A GB0229626D0 (en)	2002-12-19	2002-12-19	Organic compounds

Publications (2)

Publication Number	Publication Date
PL403456A1 true PL403456A1 (pl)	2013-05-27
PL219449B1 PL219449B1 (pl)	2015-04-30

Family

ID=27767104

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL370575A PL215581B1 (pl)	2002-02-28	2003-02-27	Pochodne 5-fenylotiazolu, kompozycje farmaceutyczne zawierajace te pochodne, zastosowanie lecznicze tych pochodnych i sposób ich wytwarzania
PL403456A PL219449B1 (pl)	2002-02-28	2003-02-27	Pochodne 5-fenylotiazolu, zawierające je kompozycje farmaceutyczne oraz lecznicze zastosowania tych związków

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL370575A PL215581B1 (pl)	2002-02-28	2003-02-27	Pochodne 5-fenylotiazolu, kompozycje farmaceutyczne zawierajace te pochodne, zastosowanie lecznicze tych pochodnych i sposób ich wytwarzania

Country Status (27)

Country	Link
US (2)	US7687637B2 (pl)
EP (1)	EP1480962B1 (pl)
JP (2)	JP4408701B2 (pl)
KR (1)	KR100688370B1 (pl)
CN (1)	CN100548996C (pl)
AR (1)	AR038703A1 (pl)
AT (1)	ATE521598T1 (pl)
AU (1)	AU2003214080A1 (pl)
BR (1)	BR0308030A (pl)
CA (1)	CA2477601C (pl)
CO (1)	CO5611131A2 (pl)
CY (2)	CY1112084T1 (pl)
DK (2)	DK2311818T3 (pl)
EC (2)	ECSP045253A (pl)
ES (2)	ES2405816T3 (pl)
IL (2)	IL163691A0 (pl)
MX (1)	MXPA04008362A (pl)
MY (1)	MY156407A (pl)
NO (1)	NO329175B1 (pl)
NZ (1)	NZ534657A (pl)
PE (1)	PE20030968A1 (pl)
PL (2)	PL215581B1 (pl)
PT (2)	PT1480962E (pl)
RU (2)	RU2436780C2 (pl)
SI (1)	SI1480962T1 (pl)
TW (1)	TWI314928B (pl)
WO (1)	WO2003072557A1 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2344653A1 (en)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en)	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
AU2004212490B2 (en)	2003-02-10	2008-05-15	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
KR20120045062A (ko) *	2003-03-31	2012-05-08	가부시키가이샤 아루떼꾸 우에노	혈관 과투과 질환의 치료방법
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
PT1709019E (pt) *	2004-01-12	2007-08-27	Serono Lab	Derivados de tiazol e sua utilização
AU2005279045B2 (en)	2004-08-28	2009-11-26	Astrazeneca Ab	Pyrimidine sulphonamide derivatives as chemokine receptor modulators
RU2403258C2 (ru)	2004-10-07	2010-11-10	Бёрингер Ингельхайм Интернациональ Гмбх	Тиазолилдигидроиндазолы
UY29149A1 (es) *	2004-10-07	2006-05-31	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
EP1964577B1 (en) *	2005-05-05	2016-04-13	GlaxoSmithKline Intellectual Property Development Limited	Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
AU2006251157B2 (en)	2005-05-24	2011-09-01	Merck Serono Sa	Thiazole derivatives and use thereof
CA2607385C (en) *	2005-05-24	2014-12-16	Laboratoires Serono S.A.	Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
WO2007064891A1 (en) *	2005-12-01	2007-06-07	The Scripps Research Institute	Compositions and methods for inducing neuronal differentiation
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
AU2007219509A1 (en) *	2006-01-18	2007-09-07	Siena Biotech S.P.A	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CN101421265A (zh) *	2006-01-18	2009-04-29	安姆根有限公司	作为蛋白激酶b(pkb)抑制剂的噻唑化合物
AU2007206860A1 (en) *	2006-01-23	2007-07-26	Laboratoires Serono S.A.	Thiazole derivatives and use thereof
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
US20070238746A1 (en) *	2006-04-06	2007-10-11	Trixi Brandl	Thiazolyl-dihydro-chinazoline
US7517995B2 (en) *	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
WO2007129044A1 (en) *	2006-05-03	2007-11-15	Astrazeneca Ab	Thiazole derivatives and their use as anti-tumour agents
GB0608823D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
GB0608854D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	P13 kinase inhibitors
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
US7589212B2 (en) *	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
RU2435763C2 (ru) *	2006-06-27	2011-12-10	Дзе Проктер Энд Гэмбл Компани	Ингибиторы тирозинфосфатазы белка человека и способы применения
ATE414281T1 (de)	2006-08-03	2008-11-15	Cellzome Ag	Verfahren zur identifizierung von molekülen die mit pi3k interagieren und verfahren zur reinigung von pi3k
AU2007290359B2 (en) *	2006-09-01	2012-09-20	Vertex Pharmaceuticals Incorporated	5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
EP2117526B1 (en)	2006-11-29	2013-04-03	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100031528A (ko)	2007-06-01	2010-03-22	더 트러스티즈 오브 프린스턴 유니버시티	숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
AU2008276521B2 (en)	2007-07-17	2011-11-03	Amgen Inc.	Heterocyclic modulators of PKB
WO2009011871A2 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
KR20100093129A (ko) *	2007-12-20	2010-08-24	노파르티스 아게	Ｐｉ３ 키나제 억제제로서 사용되는 티아졸 유도체
WO2009098021A1 (en)	2008-02-04	2009-08-13	Cellzome Ag	Selectivity profiling of pi3k interacting molecules against multiple targets
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) *	2008-09-22	2013-06-12	北京摩力克科技有限公司	噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
BRPI1008308B8 (pt) *	2009-02-27	2021-05-25	Teijin Pharma Ltd	processo para produzir um composto
WO2010125799A1 (ja) *	2009-04-27	2010-11-04	塩野義製薬株式会社	Pi3k阻害活性を有するウレア誘導体
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
ES2432671T3 (es)	2009-07-02	2013-12-04	Novartis Ag	2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
GB0913345D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	New combination 802
US8637557B2 (en)	2009-10-19	2014-01-28	Taisho Pharmaceutical Co., Ltd	Aminothiazole derivative
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
SG183155A1 (en)	2010-02-03	2012-09-27	Signal Pharm Llc	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
GB2485886A (en) *	2010-11-24	2012-05-30	Lithera Inc	Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
GB201021992D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	Compound
GB201021979D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	New compound
US20130158023A1 (en)	2011-08-03	2013-06-20	Signal Pharmaceuticals, Llc	Identification of gene expression as a predictive biomarker for lkb1 status
US9309236B2 (en)	2011-10-05	2016-04-12	The Board Of Trustees Of The Leland Stanford Junior University	PI-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
CN104204192A (zh)	2012-02-13	2014-12-10	加米达细胞有限公司	间充质干细胞调理的基质及其产生和使用方法
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EA030726B1 (ru)	2013-04-17	2018-09-28	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
AU2014254059B2 (en)	2013-04-17	2019-06-06	Signal Pharmaceuticals, Llc	Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908353C (en)	2013-04-17	2021-11-02	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
CA2908957C (en)	2013-04-17	2021-05-18	Signal Pharmaceuticals, Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9505764B2 (en)	2013-04-17	2016-11-29	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
HK1221168A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es)	2013-04-17	2019-09-27	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
HK1223286A1 (zh)	2013-05-29	2017-07-28	西格诺药品有限公司	7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
CN104418858B (zh)	2013-08-30	2018-12-11	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
DE102013226711A1 (de) *	2013-12-19	2015-06-25	Beiersdorf Ag	Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja)	2014-04-16	2017-04-20	シグナルファーマシューティカルズ，エルエルシー	１−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2015162584A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
WO2016065583A1 (en)	2014-10-30	2016-05-06	Merck Sharp & Dohme Corp.	Oxazole orexin receptor antagonists
AU2016317582B2 (en) *	2015-09-04	2018-09-27	Corteva Agriscience Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
AU2016317579B2 (en) *	2015-09-04	2018-10-04	Corteva Agriscience Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
AU2016318336B2 (en) *	2015-09-10	2018-09-27	Corteva Agriscience Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
PL3395801T3 (pl)	2015-12-16	2021-10-18	Nippon Soda Co., Ltd.	Związek aryloazolowy i środek do zwalczania szkodników
CA3012861C (en)	2016-02-01	2023-01-24	The Governing Council Of The University Of Toronto	53bp1 inhibitors
US11091472B2 (en)	2016-02-26	2021-08-17	The Regents Of The University Of California	PI-kinase inhibitors with anti-infective activity
ES2959860T3 (es)	2017-06-22	2024-02-28	Celgene Corp	Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
US12000833B2 (en)	2017-11-23	2024-06-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Marker for predicting the sensitivity to PI3K inhibitors
EP3941909A4 (en) *	2019-03-21	2023-01-25	The Board Of Trustees Of The Leland Stanford Junior University	Pi4-kinase inhibitors and methods of using the same
PH12022550468A1 (en) *	2019-08-28	2023-03-06	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
CN115028596B (zh) *	2021-03-03	2024-06-07	帕潘纳(北京)科技有限公司	制备苯唑草酮中间体的方法
KR20250153183A (ko)	2022-12-19	2025-10-24	카마우 테라퓨틱스, 인크.	P53 결합 단백질인 53bp1의 개선된 펩타이드 저해제
CN117384100A (zh) *	2023-10-13	2024-01-12	河南农业大学	一种多菌灵半抗原、人工抗原及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB951885A (en) *	1961-05-13	1964-03-11	Sankyo Co	A new process for the preparation of thiazole compounds
OA01933A (fr)	1965-04-06	1970-02-04	Pechiney Saint Gobain	Dérivés du thiazole.
US3749775A (en) *	1969-07-07	1973-07-31	Stauffer Chemical Co	Insecticidal 2-aminothiazole phosphates and phosphonates
FR2429210A1 (fr) *	1978-06-19	1980-01-18	Fabre Sa Pierre	Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme
US4511574A (en) *	1981-01-08	1985-04-16	Mitsui Toatsu Kagaku Kabushiki Kaisha	N-(4-Phenyl-2-thiazolyl)carbamate derivatives
JPS57136579A (en)	1981-01-21	1982-08-23	Mitsui Toatsu Chem Inc	Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
DE3413755A1 (de)	1984-04-12	1985-10-24	Basf Ag, 6700 Ludwigshafen	Thiazolylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPH0725754B2 (ja)	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
DE3864248D1 (de) *	1987-12-14	1991-09-19	Sawai Seiyaku Kk	Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US4891375A (en)	1988-01-13	1990-01-02	Pfizer Inc.	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
CA2074933C (en)	1990-11-30	2002-12-03	Masatoshi Chihiro	Thiazole derivatives as active superoxide radical inhibitors
DE4401911A1 (de)	1994-01-24	1995-08-03	Basf Ag	Verwendung von Aryl- oder Heteroarylazoanilinen in der nichtlinearen Optik
WO1996003392A1 (en)	1994-07-27	1996-02-08	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
AU689972B2 (en) *	1994-11-29	1998-04-09	Hisamitsu Pharmaceutical Co., Inc.	Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9625843D0 (en)	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
HUP0101704A3 (en)	1997-12-22	2002-12-28	Bayer Corp Pittsburgh	Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
US6100282A (en) *	1998-01-02	2000-08-08	Hoffman-La Roche Inc.	Thiazole derivatives
SI0928790T1 (en)	1998-01-02	2003-06-30	F. Hoffmann-La Roche Ag	Thiazole derivatives
US6043254A (en) *	1998-04-03	2000-03-28	Boehringer Ingelheim Pharma Kg	Indolinones having kinase-inhibiting activity
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1857443B1 (en)	2000-01-24	2012-03-28	AstraZeneca AB	Therapeutic morpholino-substituted compounds
DK2223922T3 (en)	2000-04-25	2016-06-06	Icos Corp	Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
CN100457753C (zh) *	2000-07-26	2009-02-04	布里斯托尔-迈尔斯斯奎布公司	依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
EP1847263A3 (en)	2000-12-18	2009-08-26	Institute of Medicinal Molecular Design, Inc.	Inhibitors against the production and release of inflammatory cytokines
AR039059A1 (es)	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003015717A2 (en) *	2001-08-17	2003-02-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6812653B2 (en) *	2002-07-26	2004-11-02	Richard S. Bellivean	Method and apparatus for controlling images with image projection lighting devices
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds

2003
- 2003-02-26 AR ARP030100626A patent/AR038703A1/es active IP Right Grant
- 2003-02-26 TW TW092104036A patent/TWI314928B/zh not_active IP Right Cessation
- 2003-02-26 PE PE2003000188A patent/PE20030968A1/es not_active Application Discontinuation
- 2003-02-26 MY MYPI20030662A patent/MY156407A/en unknown
- 2003-02-27 SI SI200332074T patent/SI1480962T1/sl unknown
- 2003-02-27 DK DK10174528.9T patent/DK2311818T3/da active
- 2003-02-27 EP EP03709730A patent/EP1480962B1/en not_active Expired - Lifetime
- 2003-02-27 IL IL16369103A patent/IL163691A0/xx unknown
- 2003-02-27 PT PT03709730T patent/PT1480962E/pt unknown
- 2003-02-27 RU RU2009132712/04A patent/RU2436780C2/ru not_active IP Right Cessation
- 2003-02-27 PT PT101745289T patent/PT2311818E/pt unknown
- 2003-02-27 PL PL370575A patent/PL215581B1/pl unknown
- 2003-02-27 WO PCT/EP2003/002036 patent/WO2003072557A1/en not_active Ceased
- 2003-02-27 PL PL403456A patent/PL219449B1/pl unknown
- 2003-02-27 ES ES10174528T patent/ES2405816T3/es not_active Expired - Lifetime
- 2003-02-27 NZ NZ534657A patent/NZ534657A/en not_active IP Right Cessation
- 2003-02-27 CN CNB038047969A patent/CN100548996C/zh not_active Expired - Fee Related
- 2003-02-27 AU AU2003214080A patent/AU2003214080A1/en not_active Abandoned
- 2003-02-27 US US10/504,259 patent/US7687637B2/en not_active Expired - Fee Related
- 2003-02-27 MX MXPA04008362A patent/MXPA04008362A/es active IP Right Grant
- 2003-02-27 RU RU2004129279/04A patent/RU2378263C2/ru not_active IP Right Cessation
- 2003-02-27 BR BR0308030-7A patent/BR0308030A/pt not_active IP Right Cessation
- 2003-02-27 CA CA2477601A patent/CA2477601C/en not_active Expired - Fee Related
- 2003-02-27 KR KR1020047013419A patent/KR100688370B1/ko not_active Expired - Fee Related
- 2003-02-27 JP JP2003571263A patent/JP4408701B2/ja not_active Expired - Fee Related
- 2003-02-27 DK DK03709730.0T patent/DK1480962T3/da active
- 2003-02-27 AT AT03709730T patent/ATE521598T1/de active
- 2003-02-27 ES ES03709730T patent/ES2372597T3/es not_active Expired - Lifetime
2004
- 2004-08-23 IL IL163691A patent/IL163691A/en not_active IP Right Cessation
- 2004-08-28 EC EC2004005253A patent/ECSP045253A/es unknown
- 2004-09-15 CO CO04091790A patent/CO5611131A2/es active IP Right Grant
- 2004-09-27 NO NO20044095A patent/NO329175B1/no not_active IP Right Cessation
2009
- 2009-08-12 JP JP2009187248A patent/JP2009298799A/ja active Pending
- 2009-12-17 US US12/640,479 patent/US8129541B2/en not_active Expired - Fee Related
2010
- 2010-08-30 EC EC2010005253A patent/ECSP105253A/es unknown
2011
- 2011-11-24 CY CY20111101144T patent/CY1112084T1/el unknown
2013
- 2013-04-16 CY CY20131100312T patent/CY1114083T1/el unknown

Also Published As

Publication number	Publication date
ATE521598T1 (de)	2011-09-15
PT2311818E (pt)	2013-05-15
ECSP105253A (es)	2010-09-30
SI1480962T1 (sl)	2011-12-30
RU2436780C2 (ru)	2011-12-20
EP1480962B1 (en)	2011-08-24
JP4408701B2 (ja)	2010-02-03
KR100688370B1 (ko)	2007-03-02
US20050119320A1 (en)	2005-06-02
NZ534657A (en)	2007-05-31
CO5611131A2 (es)	2006-02-28
ES2372597T3 (es)	2012-01-24
US20100093690A1 (en)	2010-04-15
US7687637B2 (en)	2010-03-30
DK1480962T3 (da)	2011-12-05
IL163691A (en)	2010-11-30
WO2003072557A1 (en)	2003-09-04
RU2004129279A (ru)	2005-06-27
PT1480962E (pt)	2011-12-15
EP1480962A1 (en)	2004-12-01
CN1639139A (zh)	2005-07-13
TW200303750A (en)	2003-09-16
CY1112084T1 (el)	2015-11-04
RU2378263C2 (ru)	2010-01-10
CN100548996C (zh)	2009-10-14
JP2005522458A (ja)	2005-07-28
CY1114083T1 (el)	2016-07-27
PL219449B1 (pl)	2015-04-30
HK1071363A1 (en)	2005-07-15
KR20040091674A (ko)	2004-10-28
RU2009132712A (ru)	2011-03-10
BR0308030A (pt)	2004-12-28
ES2405816T3 (es)	2013-06-03
DK2311818T3 (da)	2013-05-06
PL215581B1 (pl)	2013-12-31
AU2003214080A1 (en)	2003-09-09
MXPA04008362A (es)	2004-11-26
CA2477601A1 (en)	2003-09-04
NO20044095L (no)	2004-11-02
CA2477601C (en)	2011-05-24
JP2009298799A (ja)	2009-12-24
PE20030968A1 (es)	2004-01-12
MY156407A (en)	2016-02-26
US8129541B2 (en)	2012-03-06
NO329175B1 (no)	2010-09-06
IL163691A0 (en)	2005-12-18
AR038703A1 (es)	2005-01-26
TWI314928B (en)	2009-09-21
PL370575A1 (pl)	2005-05-30
ECSP045253A (es)	2004-09-28

Publication	Publication Date	Title
SI1480962T1 (sl)	2011-12-30	5-feniltiazolni derivati in uporaba kot PI3 kinazni inhibitorji
PL376789A1 (pl)	2006-01-09	Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
IL176233A0 (en)	2006-10-05	Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
IL164651A0 (en)	2005-12-18	Thiazolidinones and the use thereof as polo-like kinase inhibitors
PL1648426T3 (pl)	2014-05-30	Pochodne benzimidazolu i ich zastosowanie jako inhibitorów kinaz białkowych
ZA200408386B (en)	2006-05-31	Substituted benzazoles and use thereof as Raf kinase inhibitors
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
PL375447A1 (pl)	2005-11-28	Inhibitory kinaz białkowych i ich zastosowania
PL375877A1 (pl)	2005-12-12	Pochodne hydantoiny i ich zastosowanie jako inhibitorów TACE
PL372814A1 (pl)	2005-08-08	Tiazolidyno-4-karbonitryle i analogi oraz ich zastosowanie jako inhibitory dipeptydylo-peptydaz
PL373649A1 (pl)	2005-09-05	Inhibitory kinazy
AU2003259749A1 (en)	2004-02-25	3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SI1569907T1 (sl)	2016-06-30	Na nikotinamidu osnovani kinazni inhibitorji
PL377791A1 (pl)	2006-02-20	Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
EP1558609A4 (en)	2008-05-28	KINASE INHIBITORS
AU2003232848A8 (en)	2003-12-31	Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003220437A1 (en)	2003-10-08	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
EP1569907A4 (en)	2007-10-31	NICOTINAMIDE-BASED KINASE HEMMER
AU2003210983A8 (en)	2003-09-04	Kinase inhibitors and methods of use thereof
AP1963A (en)	2009-03-03	Substituted pyrrole derivatives and their use as HMG-co inhibitors
IL176772A0 (en)	2006-10-31	Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
AU2003297612A8 (en)	2004-06-23	2-substituted-3-propenamide derivatives and methods of using the same
AU2003212515A8 (en)	2003-09-16	Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
AU2003218715A8 (en)	2003-09-22	Azepane derivatives and their use as atk1 inhibitors